Tasly Pharmaceutical
Tasly Pharmaceutical is a company that provides global market services with tech systems in the GMP.
Launch date
Employees
Market cap
AUD4.4b
Enterprise valuation
AUD3.7b (Public information from Sep 2024)
Share price
CNY13.9 600535.SS
Tianjin Tianjin Shi (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 13.6b | 8.0b | 8.6b | 8.7b | 9.2b | 9.8b | 10.3b |
| % growth | (29 %) | (41 %) | 8 % | 1 % | 6 % | 7 % | 5 % |
| EBITDA | 2.4b | 3.6b | 1.8b | 1.9b | 2.0b | 2.2b | 2.4b |
| % EBITDA margin | 18 % | 45 % | 21 % | 22 % | 22 % | 23 % | 23 % |
| Profit | 1.1b | 2.4b | (257m) | 1.1b | 1.2b | 1.4b | 1.5b |
| % profit margin | 8 % | 30 % | (3 %) | 12 % | 13 % | 14 % | 15 % |
| EV / revenue | 1.7x | 2.9x | 1.7x | 2.7x | 2.2x | 1.9x | 1.9x |
| EV / EBITDA | 9.6x | 6.4x | 8.4x | 12.6x | 9.8x | 8.3x | 8.0x |
| R&D budget | 689m | 580m | 844m | 917m | - | - | - |
| R&D % of revenue | 5 % | 7 % | 10 % | 11 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Related Content
Recent News about Tasly Pharmaceutical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
